N. Sergeant, Neurobiology of Disease, vol.129, pp.217-233, 2019.

, Amandine Descat: LC-MS/MS quantification of the compound. Sabiha Eddarkaoui: Design and performance of the biological assays. Caroline Evrard: Cell assays. Amaury Farce: Molecular modeling. Marion Gay: Compounds synthesis. Malika Hamdane: Cellular model. Mostafa Kouach: LC-MS/MS quantification of the compound. Paul-Emmanuel Larchanché: Compounds synthesis. Cyril Laurent: Biochemical analyses of animal models. Nicolas Lefur: Compounds design and synthesis. Patricia Melnyk: Co-design the study and writing of the manuscript. Hélène Obriot: Biochemical analyses of animal models. Nicolas Sergeant: Co-design of the study and writing of the manuscript, Authors contribution David Blum: Design of the study and analysis of data. Luc Buée: Design of the study and wrote the manuscript. Valérie Buée-Scherrer: Analyses of biochemical data. Raphaelle Caillerez: Histological and stereological study. Pascal Carato: Structure activity relationship study

H. Acx, L. Chávez-gutiérrez, L. Serneels, S. Lismont, M. Benurwar et al., Signature ? amyloid profiles are produced by different ?-secretase complexes, J. Biol. Chem, vol.289, pp.4346-4355, 2014.

M. Barrier, L. Buée, S. Burlet, A. Delacourte, C. Estrella et al., Sulfate Salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, Preparation Thereof and Use of the Same, 2012.

G. Barsuto-islas, I. Grundke-iqbal, Y. C. Tung, and K. Iqbal, Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease, J. Biol. Chem, vol.288, pp.17495-17507, 2013.

K. Belarbi, K. Schindowski, S. Burnouf, R. Caillierez, M. E. Grosjean et al., Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease, Curr. Alzheimer Res, vol.6, pp.152-157, 2009.

K. Belarbi, S. Burnouf, F. J. Fernandez-gomez, C. Laurent, S. Lestavel et al., Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology, Neurobiol. Dis, vol.43, pp.486-494, 2011.

A. Bretteville, K. Ando, A. Ghestem, A. Loyens, S. Bégard et al., Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes, PLoS One, issue.4, p.4843, 1999.

V. Capurro, P. Busquet, J. P. Lopes, R. Bertorelli, G. Tarozzo et al., Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease, PLoS One, vol.8, issue.2, p.56870, 2013.

Y. Chen, J. Sun, S. Peng, H. Liao, Y. Zhang et al., Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease, Arch. Pharm, vol.346, pp.865-871, 2013.

J. Cummings, G. Lee, T. Mortsdorf, A. Ritter, and K. Zhong, Alzheimer's disease drug development pipeline: 2017. Alzheimer's Dement, Transl. Res. Clin. Interv, vol.3, pp.367-384, 2017.

B. De-strooper, Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process, Physiol. Rev, vol.90, pp.465-494, 2010.

M. Domise, S. Didier, C. Marinangeli, H. Zhao, P. Chandakkar et al., AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo, Sci. Rep, vol.6, 2016.

B. Dubois, H. H. Feldman, C. Jacova, J. L. Cummings, S. T. Dekosky et al., Revising the definition of Alzheimer's disease: a new lexicon, Lancet Neurol, vol.9, pp.1118-1127, 2010.

G. L. Ellman, K. D. Courtney, V. Andres, and R. M. Featherstone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol, vol.7, pp.88-90, 1961.

F. J. Fernandez-gomez, F. Jumeau, M. Derisbourg, S. Burnouf, H. Tran et al., Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting, J. Vis. Exp, vol.86, 2014.

M. K. Hu, Synthesis and in-vitro anticancer evaluation of bistacrine congeners, J. Pharm. Pharmacol, vol.53, pp.83-88, 2001.

K. Inoue, J. Rispoli, H. Kaphzan, E. Klann, E. I. Chen et al., Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway, Mol. Neurodegener, vol.7, pp.48-60, 2012.

N. Sergeant, Neurobiology of Disease, vol.129, pp.217-233, 2019.

L. M. Ittner, Y. D. Ke, F. Delerue, M. Bi, A. Gladbach et al., Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models, Cell, vol.142, pp.387-397, 2010.

A. Van-der-jeugd, T. Ahmed, S. Burnouf, K. Belarbi, M. Hamdame et al., Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission, Neurobiol. Learn. Mem, vol.95, issue.3, pp.296-304, 2011.

P. Jiang and N. Mizushima, LC3-and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells, Methods, vol.75, pp.13-18, 2015.

R. S. Keri, C. Quintanova, S. M. Marques, A. R. Esteves, S. M. Cardoso et al., Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease, Bioorg. Med. Chem, vol.21, pp.4559-4569, 2013.

C. Laurent, S. Burnouf, B. Ferry, V. L. Batalha, J. E. Coelho et al., A 2A adenosine receptor deletion is protective in a mouse model of Tauopathy, Mol. Psychiatry, vol.21, issue.1, pp.97-107, 2016.

H. Le-freche, J. Brouillette, F. J. Fernandez-gomez, P. Patin, R. Caillierez et al., Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment, Anesthesiology, vol.116, pp.779-787, 2012.

F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto, Alzheimer's disease: clinical trials and drug development, Lancet Neurol, vol.9, pp.702-716, 2010.

P. Melnyk, N. Sergeant, L. Buée, and A. Delacourte, Use of 1,4-bis(3-aminopropyl) Piperazine Derivatives in Therapy, p.51489, 2006.

P. Melnyk, V. Vingtdeux, S. Burlet, S. Eddarkaoui, M. E. Grosjean et al., Chloroquine and chloroquine related compounds as a model for the design of anti-Alzheimer compounds, ACS Chem. Neurosci, vol.6, pp.559-569, 2015.

D. Munoz-torrero, Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease, Curr. Med. Chem, vol.15, pp.2433-2455, 2008.

D. A. Nijholt, A. Nölle, E. S. Van-haastert, H. Edelijn, R. F. Toonen et al., Unfolded protein response activates glycogen synthase kinase-3 via selective lysosomal degradation, Neurobiol. Aging, vol.34, pp.1759-1771, 2013.

R. A. Nixon, The role of autophagy in neurodegenerative diseases, Nat. Med, vol.19, pp.983-997, 2013.

R. Pardossi-piquard and F. Checler, The physiology of the ?-amyloid precursor protein intracellular domain AICD, J. Neurochem, vol.120, pp.109-124, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00724579

F. Pickford, E. Masliah, M. Britschgi, K. Lucin, R. Narasimhan et al., The autophagy-related protein beclin1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice, J. Clin. Invest, vol.118, pp.2190-2199, 2008.

V. A. Polito, H. Li, H. Martini-stoica, B. Wang, L. Yang et al., Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB, EMBO Mol. Med, vol.6, pp.1142-1160, 2014.

A. M. Pooler, M. Polydoro, and E. A. Maury, Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease, Acta Neuropathol, vol.129, pp.895-907, 2015.

A. Ryckebusch, R. Deprez-poulain, L. Maes, M. Debreu-fontaine, E. Mouray et al., Synthesis and in vitro and in vivo antimalarial activity of N1-(7-Chloro-4-quinolyl)-1,4-bis(3-aminopropyl)piperazine derivatives, J. Med. Chem, vol.46, pp.542-557, 2003.

N. Sergeant, J. P. David, M. Goedert, R. Jakes, P. Vermersch et al., Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications, J. Neurochem, vol.69, issue.2, pp.834-844, 1997.

N. Sergeant, A. Wattez, and A. Delacourte, Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively « exon 10 » isoforms, J. Neurochem, vol.72, pp.1243-1249, 1999.

N. Sergeant, J. P. David, D. Champain, A. Ghestem, A. Wattez et al., Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease, J. Neurochem, vol.81, pp.663-672, 2002.

B. Spencer, R. Potkar, M. Trejo, E. Rockenstein, C. Patrick et al., Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases, J. Neurosci, vol.29, pp.13578-13588, 2009.

M. Takahashi, H. Miyata, F. Kametani, T. Nonaka, H. Akiyama et al., Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau, Acta Neuropathol, vol.129, pp.895-907, 2015.

J. H. Tam, C. Seah, and S. H. Pasternak, The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid, Mol. Brain, vol.7, pp.54-71, 2014.

L. Troquier, R. Caillierez, S. Burnouf, F. J. Fernandez-gomez, M. E. Grosjean et al., Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach, Curr. Alzheimer Res, vol.9, pp.397-405, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00664452

V. Vingtdeux and P. Marambaud, Identification and biology of ?-secretase, J. Neurochem, vol.120, pp.34-45, 2012.

V. Vingtdeux, M. Hamdane, A. Loyens, P. Gelé, H. Drobecq et al., Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies, J. Biol. Chem, vol.282, pp.18197-18205, 2007.

A. G. Vorobyeva, R. Lee, S. Miller, C. Longen, M. Sharoni et al., Cyclopamine modulates ?-secretase-mediated cleavage of amyloid precursor protein by altering its subcellular trafficking and lysosomal degradation, J. Biol. Chem, vol.289, pp.33258-33274, 2014.

X. Ye and Q. Cai, Snapin-mediated BACE1 retrograde transport is essential for its degradation in lysosomes and regulation of APP processing in neurons, Cell Rep, vol.6, pp.24-31, 2014.

Z. Zhang, M. Song, X. Liu, S. S. Kang, I. S. Kwon et al., Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease, Nat. Med, vol.20, pp.1254-1262, 2014.

N. Sergeant, Neurobiology of Disease, vol.129, pp.217-233, 2019.